NCT00684866View on ClinicalTrials.gov

Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

July 31, 2003

Study Completion Date

July 31, 2003

Conditions
Asthma
Interventions
DRUG

Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI

(a) Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)

DRUG

Racemic Albuterol followed by levalbuterol HFA MDI

(a) Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)

Trial Locations (11)

Unknown

Madera

San Diego

Savannah

Louisville

Cortland

Medford

Portland

Chester

Knoxville

Dallas

Houston

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT00684866 - Safety and Tolerability Study of Levalbuterol HFA and Racemic Albuterol HFA in Pediatrics Subjects With Asthma | Biotech Hunter | Biotech Hunter